Therefore, it would not be expected to enhance the ability to predict sensitivity to TP53-MDM2 inhibitors in TP53 WT tumors, so the reported predictive ability of the Jeay et al., (2015) signature in the set of 52 cancer cell lines considered by authors as TP53 WT is surprising. The gene discussed is MDM2; the disease is cancer.